Drugs / [68Ga]Ga-R54
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07577206 | Jan 2025 → Jan 2027 expected | plasma cell myeloma | National Cancer Institute, Naples | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [68Ga]Ga-R54 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07577206 ↗ |
| Route | Intravenous | “A single intravenous microdose (≤100 μg)” NCT07577206 ↗ |
| Target | CXCR4 | “A single intravenous microdose (≤100 μg) of the CXCR4-targeting radiopharmaceutical \[68Ga\]Ga-R54 is administered” NCT07577206 ↗ |